Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.

Uchihara N, Tamaki N, Marusawa H, Urawa N, Hasebe C, Arai H, Ochi H, Kondo M, Mori N, Tsuji K, Fujii H, Ogawa C, Uchida Y, Mori H, Toshimori J, Okamoto E, Shigeno M, Akahane T, Narita R, Yoshida H, Yokohama K, Kubotsu Y, Yasuda Y, Tada T, Nakamura S, Tsuchiya K, Yasui Y, Izumi N, Kurosaki M, Japanese Red Cross Liver Study Group

Open source

DOI: 10.21873/anticanres.18300
Published: 2026 Aug
Container: Anticancer research
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21873/anticanres.18300,
  title = {Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.},
  author = {Uchihara N and Tamaki N and Marusawa H and Urawa N and Hasebe C and Arai H and Ochi H and Kondo M and Mori N and Tsuji K and Fujii H and Ogawa C and Uchida Y and Mori H and Toshimori J and Okamoto E and Shigeno M and Akahane T and Narita R and Yoshida H and Yokohama K and Kubotsu Y and Yasuda Y and Tada T and Nakamura S and Tsuchiya K and Yasui Y and Izumi N and Kurosaki M and Japanese Red Cross Liver Study Group},
  year = {2026},
  journal = {Anticancer research},
  doi = {10.21873/anticanres.18300},
  url = {https://doi.org/10.21873/anticanres.18300}
}

RIS

TY  - JOUR
TI  - Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
AU  - Uchihara N
AU  - Tamaki N
AU  - Marusawa H
AU  - Urawa N
AU  - Hasebe C
AU  - Arai H
AU  - Ochi H
AU  - Kondo M
AU  - Mori N
AU  - Tsuji K
AU  - Fujii H
AU  - Ogawa C
AU  - Uchida Y
AU  - Mori H
AU  - Toshimori J
AU  - Okamoto E
AU  - Shigeno M
AU  - Akahane T
AU  - Narita R
AU  - Yoshida H
AU  - Yokohama K
AU  - Kubotsu Y
AU  - Yasuda Y
AU  - Tada T
AU  - Nakamura S
AU  - Tsuchiya K
AU  - Yasui Y
AU  - Izumi N
AU  - Kurosaki M
AU  - Japanese Red Cross Liver Study Group
PY  - 2026
JO  - Anticancer research
DO  - 10.21873/anticanres.18300
UR  - https://doi.org/10.21873/anticanres.18300
ER  -

APA

N, U., N, T., H, M., N, U., C, H., H, A., H, O., M, K., N, M., K, T., H, F., C, O., Y, U., H, M., J, T., E, O., M, S., T, A., R, N., H, Y., K, Y., Y, K., Y, Y., T, T., S, N., K, T., Y, Y., N, I., M, K., & Group, J. R. C. L. S. (2026). Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.. Anticancer research. https://doi.org/10.21873/anticanres.18300

Source records

pubmed · retrieved 2026-09-25T18:59:16.999Z
europe-pmc · retrieved 2026-09-25T18:59:16.990Z